IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging (MRI) compatible medical devices and accessories and services. It also provides non-magnetic Intravenous (IV) infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Phone407-677-8022
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$23.08 million
Profitability
Miscellaneous
Employees83
OptionableNot Optionable
Iradimed (NASDAQ:IRMD) Frequently Asked Questions
What is Iradimed's stock symbol?
Iradimed trades on the NASDAQ under the ticker symbol "IRMD."
How will Iradimed's stock buyback program work?
Iradimed announced that its board has approved a stock repurchase plan on Sunday, June 4th 2017, which allows the company to repurchase $8,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization allows the company to purchase shares of its stock through open market purchases. Shares repurchase plans are often a sign that the company's board of directors believes its shares are undervalued.
How were Iradimed's earnings last quarter?
Iradimed Corp (NASDAQ:IRMD) issued its quarterly earnings results on Tuesday, October, 30th. The medical equipment provider reported $0.14 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.10 by $0.04. The medical equipment provider had revenue of $7.62 million for the quarter, compared to the consensus estimate of $7.43 million. Iradimed had a net margin of 16.59% and a return on equity of 11.72%. View Iradimed's Earnings History.
When is Iradimed's next earnings date?
What guidance has Iradimed issued on next quarter's earnings?
Iradimed updated its FY 2018 earnings guidance on Tuesday, October, 30th. The company provided earnings per share (EPS) guidance of $0.50-0.51 for the period, compared to the Thomson Reuters consensus estimate of $0.47. The company issued revenue guidance of $30-30.2 million, compared to the consensus revenue estimate of $30.23 million.Iradimed also updated its Q4 2018 guidance to $0.12-0.13 EPS.
What price target have analysts set for IRMD?
1 brokerages have issued 1 year price objectives for Iradimed's stock. Their forecasts range from $35.00 to $35.00. On average, they anticipate Iradimed's share price to reach $35.00 in the next year. This suggests a possible upside of 35.7% from the stock's current price. View Analyst Price Targets for Iradimed.
What is the consensus analysts' recommendation for Iradimed?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iradimed in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Iradimed.
Has Iradimed been receiving favorable news coverage?
News coverage about IRMD stock has been trending neutral on Sunday, InfoTrie Sentiment reports. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Iradimed earned a media sentiment score of 0.1 on InfoTrie's scale. They also assigned press coverage about the medical equipment provider a news buzz of 4.0 out of 10, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next few days.
Who are some of Iradimed's key competitors?
Some companies that are related to Iradimed include Cryolife (CRY), Cardiovascular Systems (CSII), Orthofix Medical (OFIX), Intersect ENT (XENT), AngioDynamics (ANGO), Cerus (CERS), OraSure Technologies (OSUR), SurModics (SRDX), SI-Bone (SIBN), Anika Therapeutics (ANIK), Inovio Pharmaceuticals (INO), Antares Pharma (ATRS), LeMaitre Vascular (LMAT), Orthopediatrics (KIDS) and Axonics Modulation Technologies (AXNX).
Who are Iradimed's key executives?
Iradimed's management team includes the folowing people:
- Roger Susi, Chairman, President & Chief Executive Officer
- John McCreery, Chief Operating Officer
- Christopher K. Scott, Chief Financial & Accounting Officer, Secretary
- Louis Waldman, Controller
- Brent Johnson, Executive VP-Worldwide Sales & Marketing
Who are Iradimed's major shareholders?
Iradimed's stock is owned by many different of institutional and retail investors. Top institutional investors include Navellier & Associates Inc (1.07%). Company insiders that own Iradimed stock include Christopher K Scott, Francis X Casey, John K Mccreery, Louis S Waldman, Monty K Allen, Roger E Susi and Steven M Nardi. View Institutional Ownership Trends for Iradimed.
Which institutional investors are buying Iradimed stock?
How do I buy shares of Iradimed?
Shares of IRMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Iradimed's stock price today?
One share of IRMD stock can currently be purchased for approximately $25.80.
How big of a company is Iradimed?
Iradimed has a market capitalization of $282.10 million and generates $23.08 million in revenue each year. The medical equipment provider earns $490,000.00 in net income (profit) each year or $0.08 on an earnings per share basis. Iradimed employs 83 workers across the globe.
What is Iradimed's official website?
How can I contact Iradimed?
Iradimed's mailing address is 1025 Willa Springs Dr., Winter Springs FL, 32708. The medical equipment provider can be reached via phone at 407-677-8022 or via email at [email protected]
MarketBeat Community Rating for Iradimed (NASDAQ IRMD)
MarketBeat's community ratings are surveys of what our community members think about Iradimed and other stocks. Vote "Outperform" if you believe IRMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IRMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
